Sotatercept is a first-in-class activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein under investigation for the treatment of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) in adult patients on stable background therapy.